HALO
HALOZYME THERAPEUTICS, INC.
Key Financials
Gross Profit
$6.2M
↑ 77.7%
Operating Income
$469.0M
↓ 15.0%
EPS (Diluted)
$2.56
↓ 25.4%
Revenue
$1.4B
↑ 37.6%
Total Liabilities
$2.5B
↑ 45.7%
Net Income
$316.9M
↓ 28.6%
Shareholders' Equity
$48.8M
↓ 86.6%
Total Assets
$2.5B
↑ 22.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 5/15/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 144 | 5/11/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| 4 | 5/7/2026 | View on SEC |
| 4 | 5/7/2026 | View on SEC |
| 4 | 5/7/2026 | View on SEC |
| 4 | 5/7/2026 | View on SEC |
| 4 | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | HALO |
| Company Name | HALOZYME THERAPEUTICS, INC. |
| CIK | 1159036 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 794-8889 |